



Date: 11th March 2024

To,
BSE Limited
The Compliance Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 531592

Sub: Update on acquisition of 70% stake in Derren Healthcare Private Limited.

Ref: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is in continuation to our intimation dated 19th September, 2023, wherein Genpharmasec Limited ("the Company") had made disclosures under Reg. 30 of the listing regulations, 2015 informing the execution of Share Purchase Agreement [SPA] and Share Subscription cum Shareholders Agreement [SSSA] in relation to acquire of 70% stake in Derren Healthcare Private Limited in a staged manner.

Further, the Company has as on 11th March, 2024 acquired the 70% stake in Derren Healthcare Private Limited.

We are enclosing herewith the information pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular number CIR/CFD/CMD/4/2015 dated 9th September, 2015 as Annexure-A.

Kindly take the same on records for your perusal.

Thanking you,

For and behalf of the Board of Director of,
Genpharmasec Limited

HETA
DEEPAK
SHAH
Date: 2024.03.11
14:19:59 +05'30'

Digitally signed
by HETA DEEPAK
SHAH

Heta Shah

(Company Secretary & Compliance Officer)

Membership Number: A69749

Enclosure: a/a



Annexure-A

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Name: Derren Healthcare Private Limited ("DHPL") Authorized Share Capital: ₹ 50,000,000/- (Rupees five crores only) Paid up Share Capital: ₹ 50,000,000/- (Rupees five crores only) Turnover: 71.75 lacs (for the financial year ended 31st March, 2023)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, the nature of Interest and details thereof and whether the same is done at "arm's length":	No, the promoter & group companies do not have any interest in the entity Acquired, apart from Mr. Sohan Chaturvedi, CFO of the Company. Mr. Sohan Chaturvedi is a nominee Director in Derren Healthcare Private Limited.
3.	Industry to which the entity being acquired belongs:	Pharmaceutical Formulations
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	To expand the activities of Genpharmasec Limited and to make a foray in manufacturing of formulations.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition;	Completed
7.	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash Consideration - payment made through banking system.
8.	Cost of acquisition or the price at which the shares are acquired;	35,00,000 Equity Shares of face value of Rs. 10/- per share- Cost of Acquisition Rs. 12,63,95,377/- & 13,84,275 Equity Shares of face value of Rs. 10/- per share- Cost of Acquisition Rs. 5,00,00,000/-
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	70% equity shares acquired by Genpharmasec Limited.
10.	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	DHPL was incorporated on 8 th October 2018. Turnover of last three financial years: 2020-21: Nil 2021-22: Nil 2022-23: 71.75 lacs